Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade F 10.74 2.48% 0.26
GLYC closed up 2.95 percent on Tuesday, January 15, 2019, on 51 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical GLYC trend table...

Date Alert Name Type % Chg
Jan 15 NR7 Range Contraction 2.48%
Jan 15 Wide Bands Range Expansion 2.48%
Jan 15 Overbought Stochastic Strength 2.48%
Jan 14 Weak + Overbought Other 5.50%
Jan 14 Wide Bands Range Expansion 5.50%
Jan 14 Overbought Stochastic Strength 5.50%
Jan 11 Stochastic Sell Signal Bearish 0.56%
Jan 11 NR7 Range Contraction 0.56%
Jan 11 Weak + Overbought Other 0.56%
Jan 11 Wide Bands Range Expansion 0.56%

Older signals for GLYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.05
52 Week Low 8.29
Average Volume 332,741
200-Day Moving Average 14.5834
50-Day Moving Average 11.1162
20-Day Moving Average 9.9415
10-Day Moving Average 10.524
Average True Range 0.6786
ADX 18.63
+DI 17.1451
-DI 19.18
Chandelier Exit (Long, 3 ATRs ) 9.1542
Chandelier Exit (Short, 3 ATRs ) 10.325799999999999
Upper Bollinger Band 11.4512
Lower Bollinger Band 8.4318
Percent B (%b) 0.68
BandWidth 30.371674
MACD Line -0.079
MACD Signal Line -0.2535
MACD Histogram 0.1745
Fundamentals Value
Market Cap 342.94 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -7.82
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.13
Resistance 3 (R3) 11.07 10.81 11.02
Resistance 2 (R2) 10.81 10.64 10.83 10.98
Resistance 1 (R1) 10.64 10.54 10.73 10.70 10.95
Pivot Point 10.38 10.38 10.42 10.40 10.38
Support 1 (S1) 10.21 10.21 10.30 10.27 10.01
Support 2 (S2) 9.95 10.11 9.97 9.98
Support 3 (S3) 9.78 9.95 9.94
Support 4 (S4) 9.84